Lamivudine has been evaluated in numerous clinical trials spanning Early Phase 1 through Phase 4, primarily focusing on HIV-1, HIV-2, chronic hepatitis B, and complications such as hepatocellular carcinoma and tuberculosis co-infection. Sponsored by academic institutions, government bodies like NIAID, and pharmaceutical companies such as Merck Sharp & Dohme, these studies cover recruitment statuses ranging from active and completed to terminated or withdrawn. Recent protocols also investigate novel indications, including intra-ocular applications for retinal detachment.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07393659 | RECRUITING | HIV Infections |
ViiV Healthcare |
2026-07-21 | PHASE3 |
| NCT07792096 | NOT_YET_RECRUITING | HIV Infection |
University College, London |
2026-11 | PHASE3 |
| NCT06428045 | RECRUITING | High Grade Glioma |
University of Miami |
2025-04-15 | PHASE1 |
| NCT04375800 | RECRUITING | Human Immunodeficiency Virus (HIV) Infection |
Merck Sharp & Dohme LLC |
2021-02-03 | PHASE2 |
| NCT06356740 | NOT_YET_RECRUITING | Systemic Lupus Erythematosus |
Hospices Civils de Lyon |
2024-09-01 | PHASE2 |
| NCT07631897 | NOT_YET_RECRUITING | HIV; Art Therapy; TB - Tuberculosis |
Shanghai Public Health Clinical Center |
2026-06 | PHASE4 |
| NCT06497465 | RECRUITING | Tuberculosis; HIV |
Johns Hopkins University |
2025-09-18 | PHASE3 |
| NCT06203132 | RECRUITING | HIV-1-infection |
ANRS, Emerging Infectious Diseases |
2025-01-27 | PHASE3 |
| NCT07673965 | NOT_YET_RECRUITING | HIV (Human Immunodeficiency Virus); Sleep |
University of Witwatersrand, South Africa |
2026-08-20 | PHASE4 |
| NCT04696575 | RECRUITING | Extensive Stage Lung Small Cell Carcinoma |
Roswell Park Cancer Institute |
2021-07-02 | PHASE2 |
| NCT05373758 | RECRUITING | HIV Infections; AIDS; Virologic Failure |
Massachusetts General Hospital |
2024-02-07 | |
| NCT07058974 | ACTIVE_NOT_RECRUITING | Smokers; Former Smokers |
Icahn School of Medicine at Mount Sinai |
2025-08-12 | PHASE1 |
| NCT07202546 | RECRUITING | HIV Infections |
ViiV Healthcare |
2026-02-11 | PHASE2 |
| NCT07640503 | ENROLLING_BY_INVITATION | Rett Syndrome |
Maria Denise Fernandes Carvalho de Andrade |
2025-11-05 | PHASE2 |
| NCT06774872 | RECRUITING | HIV-1-infection |
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida |
2025-04-30 | PHASE2 |
| NCT07031063 | RECRUITING | HIV Infection; Metabolic Syndrome; Antiretroviral Treatment |
Instituto Mexicano del Seguro Social |
2025-04-01 | PHASE4 |
| NCT06967753 | RECRUITING | HIV; HIV-1 |
UBATEC |
2025-07-31 | PHASE4 |
| NCT06494579 | ACTIVE_NOT_RECRUITING | Relapsed/Refractory Solid Tumors |
Thomas Marron |
2024-09-26 | PHASE1; PHASE2 |
| NCT07678268 | RECRUITING | HIV Infection; Antiretroviral Therapy; Lentivirus Infections |
Instituto Mexicano del Seguro Social |
2025-07-10 | PHASE4 |
| NCT06485154 | RECRUITING | HIV Prevention |
University of Witwatersrand, South Africa |
2024-06-01 | PHASE4 |
| NCT07075146 | RECRUITING | HIV - Human Immunodeficiency Virus; Obesity; Overweight and/or Obesity |
José Antonio Mata Marín |
2025-05-05 | PHASE3 |
| NCT06580873 | NOT_YET_RECRUITING | HIV-1-infection; Opioid Use Disorder |
Saskatchewan Health Authority - Regina Area |
2024-09-30 | PHASE4 |
| NCT05979311 | ACTIVE_NOT_RECRUITING | HIV; HIV Infections |
ViiV Healthcare |
2024-02-21 | PHASE3 |
| NCT06034938 | RECRUITING | Hiv |
University Hospital, Caen |
2024-02-08 | PHASE2 |
| NCT06907056 | RECRUITING | HIV Infection |
José Antonio Mata Marín |
2023-11-09 | PHASE4 |
| NCT07006246 | ACTIVE_NOT_RECRUITING | HIV Infection |
Professor Francois Venter |
2023-05-19 | PHASE4 |
| NCT06602622 | RECRUITING | HIV; HIV Associate Weight Loss; HIV-1 Infection; Integrase Inhibitors, HIV; HIV PROTEASE INHIB; Weight Change; Weight Loss |
Instituto Mexicano del Seguro Social |
2024-08-14 | PHASE4 |
| NCT06138600 | UNKNOWN | HIV Infections |
University of Witwatersrand, South Africa |
2023-11-01 | PHASE3 |
| NCT04337450 | ACTIVE_NOT_RECRUITING | HIV Infections |
PENTA Foundation |
2022-04-22 | PHASE2; PHASE3 |
| NCT05917509 | COMPLETED | HIV Infections |
ViiV Healthcare |
2023-07-06 | PHASE3 |
| NCT06519357 | ACTIVE_NOT_RECRUITING | Mild Cognitive Impairment |
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia |
2024-10-28 | PHASE2 |
| NCT05493969 | UNKNOWN | Acquired Immunodeficiency Syndrome |
Shanghai Public Health Clinical Center |
2022-08 | PHASE4 |
| NCT05193994 | TERMINATED | Amyotrophic Lateral Sclerosis |
Macquarie University, Australia |
2022-02-24 | PHASE3 |
| NCT06658977 | TERMINATED | Amyotrophic Lateral Sclerosis; ALS |
Macquarie University, Australia |
2024-11-15 | PHASE3 |
| NCT04022967 | UNKNOWN | HIV-1-infection |
ANRS, Emerging Infectious Diseases |
2020-09-21 | PHASE3 |
| NCT06056596 | TERMINATED | Retinal Detachment; Rhegmatogenous Retinal Detachment |
University of Wisconsin, Madison |
2024-01-30 | EARLY_PHASE1 |
| NCT06811246 | COMPLETED | Healthy |
Merck Sharp & Dohme LLC |
2024-02-07 | PHASE1 |
| NCT04665375 | TERMINATED | Hiv; Weight Gain |
University Health Network, Toronto |
2021-04-26 | PHASE4 |
| NCT04731103 | COMPLETED | Aicardi-Goutières Syndrome |
University of Edinburgh |
2022-08-24 | PHASE2 |
| NCT06056596 | Recruiting | Retinal Detachment|Rhegmatogenous Retinal Detachment |
University of Wisconsin Madison |
2024-01-30 | Early Phase 1 |
| NCT04904406 | COMPLETED | Hiv; HIV Infections; HIV Cardiomyopathy; Weight Change, Body; HIV Lipodystrophy; Cardiovascular Diseases |
Thomas Benfield |
2020-10-22 | PHASE4 |
| NCT04826562 | UNKNOWN | Human Immunodeficiency Virus |
Saint Michael's Medical Center |
2021-09-26 | PHASE4 |
| NCT04429152 | UNKNOWN | HIV-1-infection |
Professor Francois Venter |
2021-02-09 | PHASE3 |
| NCT04808973 | COMPLETED | HIV Infections; Pregnancy Related; Mother to Child Transmission |
Fundação Bahiana de Infectologia |
2021-07-01 | PHASE3 |
| NCT04585737 | COMPLETED | HIV I Infection |
Charlotte-Paige Rolle, MD |
2020-10-05 | PHASE4 |
| NCT04880785 | COMPLETED | HIV Infections |
Fundacion SEIMC-GESIDA |
2021-07-28 | PHASE2 |
| NCT04979468 | UNKNOWN | HIV-1-infection |
Societa' Italiana Di Malattie Infettive E Tropicali |
2021-03-23 | PHASE3 |
| NCT04034862 | COMPLETED | HIV Infections |
University of Liege |
2019-10-01 | PHASE3 |
| NCT04903847 | UNKNOWN | Hiv; HIV Infections; HIV Lipodystrophy; Osteoporosis; Renal Insufficiency; Weight Gain; Obesity |
Thomas Benfield |
2021-02-02 | PHASE4 |
| NCT07014189 | COMPLETED | HIV Infection; Antiretroviral Treatment; Maintenance Therapy |
Cantonal Hospital of St. Gallen |
2019-04-12 | PHASE4 |
| NCT04900038 | TERMINATED | HIV Infections |
ViiV Healthcare |
2021-08-18 | PHASE2 |
| NCT04871113 | COMPLETED | HIV Infections |
ViiV Healthcare |
2021-06-22 | PHASE2 |
| NCT04283656 | COMPLETED | Transgender Health; Gender Dysphoria; Transgender Women; Human Immunodeficiency Virus |
Thomas Jefferson University |
2022-01-04 | PHASE1 |
| NCT03870438 | COMPLETED | HIV-1 |
ANRS, Emerging Infectious Diseases |
2019-12-14 | PHASE3 |
| NCT00799864 | COMPLETED | HIV-1 |
Janssen Sciences Ireland UC |
2011-01 | PHASE2 |
| NCT05295394 | WITHDRAWN | HIV-1 Infection |
Pedro Cahn |
2019-05-22 | PHASE4 |
| NCT04233372 | COMPLETED | Hiv |
Hospital Clinic of Barcelona |
2020-08-27 | PHASE4 |
| NCT04051970 | TERMINATED | HIV-1-infection |
ANRS, Emerging Infectious Diseases |
2019-11-27 | PHASE3 |
| NCT03991013 | COMPLETED | HIV Infections |
University of Cape Town |
2019-08-08 | PHASE2 |
| NCT03869944 | UNKNOWN | HIV-1 |
ANRS, Emerging Infectious Diseases |
2019-12-04 | PHASE2 |
| NCT04311944 | UNKNOWN | HIV-1-infection |
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic |
2020-09-01 | |
| NCT03760458 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2020-09-09 | PHASE1; PHASE2 |
| NCT03682848 | COMPLETED | HIV Infections |
ViiV Healthcare |
2019-05-06 | PHASE3 |
| NCT02712801 | COMPLETED | HIV/AIDS and Infections |
National Center for Women and Children's Health, China CDC |
2016-04 | PHASE4 |
| NCT01936233 | UNKNOWN | Hepatocellular Carcinoma; Recurrence |
Fudan University |
2013-08 | PHASE3 |
| NCT04302896 | COMPLETED | Medication Adherence; HIV |
Rhonda Brand |
2020-08-31 | EARLY_PHASE1 |
| NCT02659761 | TERMINATED | Human Immunodeficiency Virus |
University College Dublin |
2016-11 | PHASE4 |
| NCT05030025 | COMPLETED | HIV-1-infection |
Mylan Inc. |
2021-08-01 | EARLY_PHASE1 |
| NCT04827134 | COMPLETED | HIV Infections |
ViiV Healthcare |
2021-05-07 | PHASE1 |
| NCT04385719 | COMPLETED | Ebola; HIV/AIDS |
Makerere University |
2021-05-05 | PHASE2 |
| NCT03563742 | TERMINATED | Human Immunodeficiency Virus Infections |
Janssen Research & Development, LLC |
2018-09-24 | PHASE3 |
| NCT03539224 | UNKNOWN | HIV-1-infection |
Instituto de Investigación Hospital Universitario La Paz |
2017-11-02 | PHASE2 |
| NCT04021290 | COMPLETED | HIV Infections |
ViiV Healthcare |
2019-11-11 | PHASE3 |
| NCT03311945 | COMPLETED | HIV Infections; HIV-1-infection; HIV Seropositivity |
Judit Pich |
2018-05-02 | PHASE3 |
| NCT03272347 | COMPLETED | HIV-1 Infection |
Merck Sharp & Dohme LLC |
2017-11-27 | PHASE2 |
| NCT02369406 | ACTIVE_NOT_RECRUITING | HIV; Pediatric AIDS |
Harvard School of Public Health (HSPH) |
2015-05-04 | PHASE2; PHASE3 |
| NCT04424264 | COMPLETED | HIV-1-infection; Tuberculosis |
Professor Francois Venter |
2019-12-05 | PHASE1 |
| NCT03988452 | UNKNOWN | Human Immunodeficiency Virus |
Makerere University |
2019-07-30 | PHASE3 |
| NCT03332095 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2018-07-02 | PHASE1; PHASE2 |
| NCT03333083 | TERMINATED | HIV Seropositivity; HIV Infections; HIV-1-infection |
Judit Pich |
2018-05-03 | PHASE3 |
| NCT03394196 | TERMINATED | HIV-2 Infection |
University of Washington |
2018-07-04 | |
| NCT03360682 | COMPLETED | HIV-1-infection; Solid Organ Transplant |
Fundacion Clinic per a la Recerca Biomédica |
2018-04-13 | PHASE4 |
| NCT03405194 | WITHDRAWN | HIV/AIDS |
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic |
2018-05-01 | |
| NCT02431975 | COMPLETED | HIV |
Columbia University |
2015-08 | PHASE4 |
| NCT03945981 | COMPLETED | HIV Infections |
ViiV Healthcare |
2019-07-02 | PHASE3 |
| NCT03144804 | COMPLETED | Colorectal Cancer Metastatic |
Massachusetts General Hospital |
2017-10-31 | PHASE2 |
| NCT02384395 | COMPLETED | HIV; Acute HIV Infection |
University of North Carolina, Chapel Hill |
2015-09 | |
| NCT04133012 | Completed | HIV-1 Infection |
ANRS Emerging Infectious Diseases|ViiV Healthcare |
2020-02-10 | Not Applicable |
| NCT02263079 | COMPLETED | Pediatric Immuno-Tolerant Chronic Hepatitis B |
Hoffmann-La Roche |
2014-06-16 | PHASE3 |
| NCT04054089 | COMPLETED | HIV Infections |
Cristina Mussini |
2020-01-23 | PHASE4 |
| NCT01491295 | UNKNOWN | Chronic Hepatitis B |
Taipei Veterans General Hospital, Taiwan |
2012-09 | PHASE4 |
| NCT03836833 | UNKNOWN | HIV |
Drugs for Neglected Diseases |
2019-06-04 | PHASE1; PHASE2 |
| NCT03033836 | COMPLETED | HIV Infections |
Fundación Huésped |
2015-12 | PHASE4 |
| NCT02945163 | COMPLETED | HIV Infections |
Shanghai Public Health Clinical Center |
2018-03-05 | PHASE4 |
| NCT03446573 | COMPLETED | HIV Infections |
ViiV Healthcare |
2018-01-18 | PHASE3 |
| NCT02150993 | COMPLETED | HIV-2 Infection |
ANRS, Emerging Infectious Diseases |
2016-01-26 | PHASE2; PHASE3 |
| NCT03067285 | COMPLETED | HIV Infections |
Fundacion SEIMC-GESIDA |
2017-09-08 | PHASE4 |
| NCT00872872 | COMPLETED | NVP Plasma Level; NVP Related Mutation; 3TC Related Mutation |
Thai Red Cross AIDS Research Centre |
2008-05 | |
| NCT03595709 | COMPLETED | HIV Infections |
Yu-Jay Corp. |
2018-12-06 | PHASE3 |
| NCT01618305 | COMPLETED | HIV Infections |
Westat |
2013-09-05 | PHASE4 |
| NCT02629822 | COMPLETED | HIV-1 Infection |
Merck Sharp & Dohme LLC |
2016-01-14 | PHASE2 |
| NCT02273765 | COMPLETED | HIV-1 Infection; Tuberculosis |
ANRS, Emerging Infectious Diseases |
2015-09-11 | PHASE3 |
| NCT02652793 | COMPLETED | Human Immunodeficiency Virus |
Judit Pich |
2015-11 | |
| NCT03205566 | COMPLETED | Hiv |
Guy's and St Thomas' NHS Foundation Trust |
2017-09-19 | PHASE4 |
| NCT02652260 | COMPLETED | HIV-1; Central Nervous System |
Merck Sharp & Dohme LLC |
2016-03-04 | PHASE2 |
| NCT02777229 | COMPLETED | HIV-1 Infection |
ANRS, Emerging Infectious Diseases |
2016-07 | PHASE3 |
| NCT03223402 | COMPLETED | HIV Infections |
Cantonal Hospital of St. Gallen |
2016-12-23 | |
| NCT01125696 | COMPLETED | HIV; Hepatitis B |
Centers for Disease Control and Prevention |
2012-05 | PHASE2 |
| NCT03441984 | COMPLETED | HIV Infections |
ViiV Healthcare |
2018-02-26 | PHASE1 |
| NCT02831764 | COMPLETED | Infection, Human Immunodeficiency Virus; HIV Infections |
ViiV Healthcare |
2016-07-18 | PHASE3 |
| NCT02369965 | COMPLETED | HIV Infections; AIDS |
Frontier Biotechnologies Inc. |
2014-02-19 | PHASE3 |
| NCT03236584 | UNKNOWN | Proportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48 |
Uijeongbu St. Mary Hospital |
2015-09-01 | PHASE3 |
| NCT02397096 | COMPLETED | HIV-1 Infection |
Merck Sharp & Dohme LLC |
2015-06-09 | PHASE3 |
| NCT02363452 | COMPLETED | Aicardi-Goutières Syndrome (AGS) |
Assistance Publique - Hôpitaux de Paris |
2015-09-10 | PHASE2 |
| NCT01900106 | COMPLETED | HIV Infection |
University of Modena and Reggio Emilia |
2013-11 | PHASE3 |
| NCT02499874 | COMPLETED | HIV |
St Stephens Aids Trust |
2015-08 | PHASE1 |
| NCT03078556 | COMPLETED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2017-03-27 | PHASE1 |
| NCT01528865 | WITHDRAWN | Lymphoma |
University of Michigan Rogel Cancer Center |
2015-12 | PHASE1; PHASE2 |
| NCT02470650 | WITHDRAWN | Patient Compliance; Antiretroviral Therapy Intolerance |
Juan A. Arnaiz |
2015-06 | PHASE4 |
| NCT02263326 | COMPLETED | HIV Infection |
Babafemi Taiwo |
2014-12 | PHASE3 |
| NCT02770508 | COMPLETED | HIV-1 Infection |
Fundación Huésped |
2015-11 | PHASE4 |
| NCT02596334 | TERMINATED | HIV |
Centre Hospitalier Régional d'Orléans |
2015-12-23 | PHASE3 |
| NCT02605954 | COMPLETED | HIV-1 Infection |
Gilead Sciences |
2015-11-18 | PHASE3 |
| NCT01580202 | COMPLETED | Malignancy; Hepatitis B |
Seoul National University Hospital |
2012-04 | PHASE3 |
| NCT02603107 | COMPLETED | HIV-1 Infection |
Gilead Sciences |
2015-11-20 | PHASE3 |
| NCT02607930 | COMPLETED | HIV-1 Infection |
Gilead Sciences |
2015-11-13 | PHASE3 |
| NCT02403674 | COMPLETED | Human Immunodeficiency Virus (HIV) |
Merck Sharp & Dohme LLC |
2015-06-05 | PHASE3 |
| NCT02827643 | UNKNOWN | Bone Density |
Mahidol University |
2016-06 | |
| NCT02527096 | COMPLETED | HIV-1 Infection |
ANRS, Emerging Infectious Diseases |
2015-09-17 | PHASE2 |
| NCT02284035 | COMPLETED | AIDS |
Juan A. Arnaiz |
2015-09-27 | PHASE3 |
| NCT02582684 | COMPLETED | HIV-1 Infection |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2015-12-08 | PHASE2 |
| NCT02509195 | COMPLETED | HIV |
St Stephens Aids Trust |
2015-08-04 | PHASE4 |
| NCT02482272 | UNKNOWN | Hepatitis B, Chronic |
Asan Medical Center |
2015-05 | PHASE4 |
| NCT00810524 | UNKNOWN | Hepatitis B, Chronic |
Sun Yat-sen University |
2007-01 | PHASE4 |
| NCT02447705 | COMPLETED | Disorder Related to Transplantation; Virus Diseases; Injury Due to Exposure to External Cause |
Chang Gung Memorial Hospital |
2013-06 | PHASE2; PHASE3 |
| NCT02632474 | COMPLETED | HIV Infections |
Shanghai Public Health Clinical Center |
2015-04 | PHASE4 |
| NCT02566707 | TERMINATED | HIV-1 Infection |
Radboud University Medical Center |
2015-08 | PHASE2 |
| NCT03178084 | COMPLETED | HIV/AIDS |
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal |
2014-10-15 | PHASE3 |
| NCT02893488 | COMPLETED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2016-09-01 | PHASE1 |
| NCT01061151 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2011-03-01 | PHASE3 |
| NCT02560649 | UNKNOWN | Chronic Hepatitis B |
Ruijin Hospital |
2015-05 | PHASE4 |
| NCT02219672 | UNKNOWN | AIDS/HIV PROBLEM |
Peking Union Medical College |
2014-07 | PHASE3 |
| NCT02738931 | COMPLETED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2016-05 | PHASE1 |
| NCT02159599 | COMPLETED | HIV Infection |
Fundacion SEIMC-GESIDA |
2014-07 | PHASE4 |
| NCT01599364 | COMPLETED | Human Immunodeficiency Virus |
Catholic University of the Sacred Heart |
2014-04 | PHASE4 |
| NCT01627223 | TERMINATED | Chronic Hepatitis B |
Taichung Veterans General Hospital |
2012-07 | PHASE4 |
| NCT01905059 | COMPLETED | HIV Infection |
ANRS, Emerging Infectious Diseases |
2014-02 | PHASE3 |
| NCT02634073 | COMPLETED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2016-01-01 | PHASE4 |
| NCT02211482 | COMPLETED | HIV-1 Infection |
Fundación Huésped |
2014-10 | PHASE4 |
| NCT01732367 | COMPLETED | Chronic Hepatitis B |
Keimyung University Dongsan Medical Center |
2012-11 | PHASE4 |
| NCT02246998 | COMPLETED | HIV-1 Infection |
Gilead Sciences |
2014-12-15 | PHASE4 |
| NCT02067767 | COMPLETED | HIV-1 Infection |
Nantes University Hospital |
2014-02 | PHASE2 |
| NCT01914744 | UNKNOWN | Non-Hodgkin Lymphoma; Hepatitis B Reactivation |
Fudan University |
2013-02 | PHASE2 |
| NCT02539576 | COMPLETED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2015-10 | PHASE1 |
| NCT01844297 | UNKNOWN | AIDS/HIV PROBLEM |
Peking Union Medical College |
2013-05 | |
| NCT01910402 | COMPLETED | Infection, Human Immunodeficiency Virus; HIV Infections |
ViiV Healthcare |
2013-08-22 | PHASE3 |
| NCT02120352 | COMPLETED | Infection, Human Immunodeficiency Virus; HIV Infections |
ViiV Healthcare |
2014-04-28 | PHASE2 |
| NCT01894269 | UNKNOWN | Hepatocellular Carcinoma |
Sun Yat-sen University |
2013-07 | PHASE4 |
| NCT01656122 | COMPLETED | HIV |
The HIV Netherlands Australia Thailand Research Collaboration |
2012-07 | PHASE2; PHASE3 |
| NCT01511237 | COMPLETED | HIV Infections |
Institut de Recherche pour le Developpement |
2011-12 | PHASE3 |
| NCT02337127 | UNKNOWN | Chronic Hepatitis B |
Kaohsiung Medical University Chung-Ho Memorial Hospital |
2011-06 | PHASE4 |
| NCT00074581 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-02 | PHASE3 |
| NCT02105987 | COMPLETED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2014-04 | PHASE3 |
| NCT02670772 | COMPLETED | Acquired Immune Deficiency Syndrome; Human Immunodeficiency Virus |
Willem Daniel Francois Venter |
2012-07 | PHASE3 |
| NCT01387022 | COMPLETED | Antiretroviral Treatment Outcomes |
Centre for the AIDS Programme of Research in South Africa |
2011-06 | |
| NCT01352715 | COMPLETED | HIV-1 Infection |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2012-03-13 | PHASE3 |
| NCT02894554 | TERMINATED | HBsAg-positive Renal Allograft Recipients |
National Taiwan University Hospital |
2014-07 | PHASE4 |
| NCT00823550 | UNKNOWN | Hepatitis B, Chronic |
Yonsei University |
2009-01 | PHASE4 |
| NCT01340950 | COMPLETED | HIV Infections; Central Nervous System Diseases; Dementia |
University of California, San Diego |
2010-07 | PHASE4 |
| NCT01471821 | COMPLETED | HIV Infection |
Juan A. Arnaiz |
2011-10 | PHASE4 |
| NCT01693679 | UNKNOWN | HBV-related Liver Cirrhosis |
Shao-quan Zhang |
2012-09 | PHASE4 |
| NCT01307488 | COMPLETED | HIV Infection |
Fundacion SEIMC-GESIDA |
2011-09 | PHASE4 |
| NCT02202473 | COMPLETED | Chronic Hepatitis B |
Southeast University, China |
PHASE4 | |
| NCT02604004 | COMPLETED | HIV INFECTIONS |
Universidade Federal de Pernambuco |
2013-04 | PHASE1 |
| NCT01641809 | COMPLETED | Infection, Human Immunodeficiency Virus; HIV Infections |
ViiV Healthcare |
2012-08-06 | PHASE2 |
| NCT01354652 | TERMINATED | Lactic Acidosis |
Asan Medical Center |
2011-05 | PHASE4 |
| NCT00719602 | COMPLETED | HIV Infections; Malaria |
International Maternal Pediatric Adolescent AIDS Clinical Trials Group |
2009-08 | EARLY_PHASE1 |
| NCT01565889 | COMPLETED | Hepatitis C; HIV |
Gilead Sciences |
2012-03 | PHASE1; PHASE2 |
| NCT00993031 | COMPLETED | Malaria; HIV Infections |
University of California, San Francisco |
2009-12-15 | PHASE3 |
| NCT01743079 | COMPLETED | Chronic Hepatitis B; Late Pregnancy; Transmission; Complication |
Beijing YouAn Hospital |
2009-01 | PHASE4 |
| NCT01751555 | COMPLETED | Hiv |
National Center for AIDS/STD Control and Prevention, China CDC |
2011-02 | PHASE4 |
| NCT01160120 | COMPLETED | HIV |
The HIV Netherlands Australia Thailand Research Collaboration |
2010-06 | PHASE2 |
| NCT01718587 | UNKNOWN | Liver Cirrhosis |
General Hospital of Chinese Armed Police Forces |
2012-11 | PHASE1; PHASE2 |
| NCT01059422 | COMPLETED | HIV Infections; Tuberculosis |
Central Institute of Epidemiology, Moscow, Russia |
2010-10 | PHASE4 |
| NCT01489046 | TERMINATED | HIV-1 Infection |
Bristol-Myers Squibb |
2011-02 | PHASE2 |
| NCT01583439 | TERMINATED | HIV Infections |
Harvard School of Public Health (HSPH) |
2012-09 | |
| NCT01088009 | COMPLETED | Compensated Chronic Hepatitis B |
Nanfang Hospital, Southern Medical University |
2010-03 | PHASE4 |
| NCT01620944 | TERMINATED | HIV |
Bristol-Myers Squibb |
2012-07-31 | PHASE3 |
| NCT00936195 | WITHDRAWN | HIV Infection; Pregnancy; Breastfeeding; HIV Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2010-01 | PHASE3 |
| NCT00986778 | WITHDRAWN | Hepatitis B, Chronic |
Bristol-Myers Squibb |
2009-12 | PHASE4 |
| NCT01139203 | UNKNOWN | Liver Transplantation; Hepatitis B |
Shanghai Jiao Tong University School of Medicine |
2009-08 | |
| NCT01608269 | COMPLETED | HiV1- Positive |
Therapeutic Concepts |
2010-11 | PHASE4 |
| NCT01275625 | COMPLETED | HIV |
ViiV Healthcare |
2011-06 | PHASE4 |
| NCT00102960 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-07 | PHASE3 |
| NCT01622790 | COMPLETED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2012-06 | PHASE1 |
| NCT01487876 | UNKNOWN | Chronic Hepatitis B |
Fuqiang Yang |
2011-09 | PHASE2 |
| NCT01788371 | COMPLETED | Hepatitis B Infection; Chronic Infection; Viremia |
Hua Zhang |
2009-03 | PHASE4 |
| NCT01318096 | UNKNOWN | HBV Coinfection; HIV Infections |
Yunnan AIDS Care Center |
2011-03 | |
| NCT01023217 | COMPLETED | Hepatitis B, Chronic |
Asan Medical Center |
2009-11 | PHASE4 |
| NCT00865007 | COMPLETED | HIV Infection; Lipodystrophy; HIV Infections |
Fundacion SEIMC-GESIDA |
2008-12 | PHASE4 |
| NCT01102972 | COMPLETED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2010-04 | PHASE4 |
| NCT01237444 | COMPLETED | HIV Infection |
Pedro Cahn |
2010-12 | PHASE3 |
| NCT01270165 | UNKNOWN | Chronic Hepatitis B |
Yonsei University |
2010-06 | PHASE3 |
| NCT00544128 | COMPLETED | HIV Infections |
International Medical Center of Japan |
2007-10 | PHASE4 |
| NCT01294761 | COMPLETED | HIV Infections |
National Center for Global Health and Medicine, Japan |
2011-02 | |
| NCT01546116 | COMPLETED | Chronic Hepatitis B |
Korea University |
2010-02 | PHASE4 |
| NCT00362635 | COMPLETED | Hepatitis B |
Bukwang Pharmaceutical |
2006-08 | PHASE3 |
| NCT01469520 | UNKNOWN | HIV; AIDS |
Elim Pediatric Pharmaceuticals Inc. |
2010-10 | PHASE1 |
| NCT00822315 | COMPLETED | HIV Infections; Tuberculosis |
ANRS, Emerging Infectious Diseases |
2009-07 | PHASE2 |
| NCT00737568 | COMPLETED | Hepatitis B |
Gilead Sciences |
2008-09 | PHASE3 |
| NCT01772940 | COMPLETED | HIV-1 Infection |
Centre Hospitalier Universitaire Saint Pierre |
2008-12 | PHASE4 |
| NCT00424814 | COMPLETED | HIV Infections |
ANRS, Emerging Infectious Diseases |
2007-03 | PHASE2; PHASE3 |
| NCT00234091 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-04 | PHASE3 |
| NCT01231555 | TERMINATED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2010-11-18 | PHASE2 |
| NCT01366547 | COMPLETED | Healthy Subjects; Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2011-06 | PHASE1 |
| NCT01014481 | TERMINATED | HIV Infections; Tuberculosis |
Bamrasnaradura Infectious Diseases Institute |
2009-10 | PHASE4 |
| NCT01353742 | COMPLETED | Hepatitis B, Chronic |
GlaxoSmithKline |
2011-02-21 | PHASE1 |
| NCT00724711 | COMPLETED | HIV Infection |
Gilead Sciences |
2008-07 | PHASE4 |
| NCT00410202 | COMPLETED | Hepatitis B, Chronic |
Bristol-Myers Squibb |
2008-03 | PHASE3 |
| NCT01220232 | COMPLETED | Healthy Volunteers |
Pfizer |
2010-11 | PHASE1 |
| NCT00307151 | COMPLETED | HIV Infections |
International Maternal Pediatric Adolescent AIDS Clinical Trials Group |
2005-12 | PHASE2 |
| NCT00958100 | COMPLETED | HIV/AIDS; Antiretroviral Therapy; HIV Infections |
Catholic University of the Sacred Heart |
2009-08 | PHASE2 |
| NCT00637663 | COMPLETED | Hepatitis B, Chronic |
Pusan National University Hospital |
2008-02 | PHASE4 |
| NCT01601899 | TERMINATED | Mitochondrial Toxicity; Metabolic Complications |
University of Witwatersrand, South Africa |
2008-10 | PHASE4 |
| NCT00346567 | COMPLETED | HIV Infections |
Rigshospitalet, Denmark |
2006-06 | |
| NCT00915655 | COMPLETED | HIV-1 Infection |
Tibotec Pharmaceuticals, Ireland |
2009-07 | PHASE2 |
| NCT00440947 | COMPLETED | Infection, Human Immunodeficiency Virus I; HIV Infection |
ViiV Healthcare |
2007-03 | PHASE3 |
| NCT00798460 | TERMINATED | Chronic Hepatitis B |
Inje University |
2008-12 | PHASE4 |
| NCT00143728 | SUSPENDED | HIV Infections |
University of British Columbia |
2004-01 | PHASE4 |
| NCT00084136 | COMPLETED | HIV Infections |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2005-05 | PHASE4 |
| NCT00885482 | COMPLETED | HIV Infections |
Catholic University of the Sacred Heart |
2009-05 | PHASE4 |
| NCT00023309 | COMPLETED | HBV (Hepatitis B Virus); Hepatitis B; Hepatitis |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2001-08 | PHASE2 |
| NCT00099632 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-03 | PHASE2 |
| NCT00100646 | COMPLETED | HIV Infections |
The Wistar Institute |
2007-03 | |
| NCT00951015 | COMPLETED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2009-07-30 | PHASE2 |
| NCT00001644 | COMPLETED | HIV Infection |
National Institute of Allergy and Infectious Diseases (NIAID) |
1997-03-03 | PHASE1 |
| NCT00985647 | COMPLETED | HIV Infections |
Kirby Institute |
2009-12 | PHASE1; PHASE2 |
| NCT00662545 | COMPLETED | HIV Infections; Hepatitis B |
University of California, San Francisco |
2008-04 | PHASE4 |
| NCT00164736 | COMPLETED | HIV Infections |
Centers for Disease Control and Prevention |
2004-03 | PHASE3 |
| NCT00672412 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2008-10 | PHASE1; PHASE2 |
| NCT00612898 | TERMINATED | HIV Infections |
Avexa |
2008-02 | PHASE2; PHASE3 |
| NCT01095835 | COMPLETED | Hepatitis B, Chronic |
Hoffmann-La Roche |
2005-02 | PHASE3 |
| NCT00555334 | UNKNOWN | Hepatocellular Carcinoma; Liver Cancer |
Sun Yat-sen University |
2007-11 | PHASE4 |
| NCT00076336 | COMPLETED | Hepatitis; Hepatitis B, Chronic; Cirrhosis |
Novartis Pharmaceuticals |
2003-12 | PHASE3 |
| NCT01438424 | COMPLETED | Hepatitis B Virus; HBV |
Bristol-Myers Squibb |
2001-01 | PHASE2 |
| NCT00549198 | COMPLETED | Infection, Human Immunodeficiency Virus I; HIV Infection |
GlaxoSmithKline |
2007-06 | PHASE4 |
| NCT00625560 | COMPLETED | Hepatitis B, Chronic |
Yonsei University |
2008-02 | PHASE4 |
| NCT00118898 | COMPLETED | HIV Infections |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2005-09 | PHASE3 |
| NCT00470041 | COMPLETED | Healthy |
University Ghent |
2007-06 | PHASE1 |
| NCT00615810 | COMPLETED | HIV Infections |
Gilead Sciences |
2008-03 | PHASE4 |
| NCT00772902 | COMPLETED | HIV-1 |
Gilead Sciences |
2008-10 | PHASE4 |
| NCT00120510 | COMPLETED | HIV Infections; Tuberculosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2007-07 | |
| NCT00768157 | UNKNOWN | Hepatocellular Carcinoma; Hepatitis B Virus; Recurrence |
Sun Yat-sen University |
2007-04 | PHASE4 |
| NCT00405925 | COMPLETED | HIV Infections |
Rijnstate Hospital |
2003-03 | PHASE3 |
| NCT00740064 | UNKNOWN | HIV Infections |
Denver Infectious Disease Consultants, PLLC |
2008-05 | PHASE4 |
| NCT00100568 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-07 | |
| NCT00332306 | UNKNOWN | Tuberculosis; Human Immunodeficiency Virus Infections |
Tuberculosis Research Centre, India |
2006-06 | PHASE3 |
| NCT00427297 | TERMINATED | HIV Infections |
University of Washington |
2007-09 | PHASE3 |
| NCT02598063 | COMPLETED | Hepatitis B, Chronic |
Hoffmann-La Roche |
2005-10 | PHASE4 |
| NCT00270296 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-06 | PHASE2 |
| NCT00307242 | COMPLETED | Chronic Hepatitis B |
Thomas Jefferson University |
2005-06-17 | PHASE4 |
| NCT00605384 | TERMINATED | Chronic Hepatitis B |
Bristol-Myers Squibb |
2008-08 | PHASE3 |
| NCT00255840 | COMPLETED | HIV Infections |
CIPRA SA |
2006-07 | |
| NCT00393484 | COMPLETED | Chronic Hepatitis B |
Bristol-Myers Squibb |
2007-02 | PHASE4 |
| NCT00146380 | COMPLETED | HIV Infections |
Centers for Disease Control and Prevention |
2003-07 | PHASE2 |
| NCT00966160 | COMPLETED | Acquired Immunodeficiency Syndrome; HIV Infections |
University of Cologne |
1999-01 | PHASE3 |
| NCT00380159 | COMPLETED | Human Immunodeficiency Virus (HIV)-1 Infection |
Alexion Pharmaceuticals, Inc. |
2006-09 | PHASE2 |
| NCT00122538 | COMPLETED | HIV Infections; AIDS |
French National Agency for Research on AIDS and Viral Hepatitis |
2006-02 | PHASE2 |
| NCT00006441 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2003-02 | |
| NCT00830856 | COMPLETED | Cryptococcal Meningitis; HIV Infections |
University of Zimbabwe |
2006-10 | |
| NCT00312091 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2006-12 | PHASE1; PHASE2 |
| NCT00450580 | COMPLETED | Infection, Human Immunodeficiency Virus I; HIV-1 Infection |
ViiV Healthcare |
2007-03 | PHASE3 |
| NCT00192634 | COMPLETED | HIV Infections |
Kirby Institute |
2005-12 | PHASE4 |
| NCT01386970 | COMPLETED | HIV |
University of Colorado, Denver |
2005-05 | PHASE4 |
| NCT00120796 | TERMINATED | Hepatitis B |
French National Agency for Research on AIDS and Viral Hepatitis |
2005-08 | PHASE3 |
| NCT00244712 | COMPLETED | HIV Infection |
GlaxoSmithKline |
2005-07 | PHASE4 |
| NCT00342355 | COMPLETED | HIV |
National Institutes of Health Clinical Center (CC) |
2004-01 | PHASE4 |
| NCT00324649 | COMPLETED | HIV-1 |
Gilead Sciences |
2006-05 | PHASE4 |
| NCT00143689 | COMPLETED | HIV; Mitochondrial Toxicity |
University of British Columbia |
2002-04 | PHASE4 |
| NCT00084149 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2004-02 | PHASE2 |
| NCT00316719 | COMPLETED | Chronic Hepatitis B |
GlaxoSmithKline |
2006-01 | PHASE3 |
| NCT00335270 | COMPLETED | HIV |
Duke University |
2006-03 | PHASE4 |
| NCT00312039 | COMPLETED | HIV Infections |
Alexion Pharmaceuticals, Inc. |
2006-03-31 | PHASE1; PHASE2 |
| NCT00275652 | COMPLETED | Hepatitis B; Cirrhosis |
Mayo Clinic |
2004-06 | PHASE3 |
| NCT00350272 | COMPLETED | HIV Infections |
Alexion Pharmaceuticals, Inc. |
2006-05 | PHASE2 |
| NCT00006617 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00100594 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-05 | |
| NCT00455585 | COMPLETED | HIV Infections |
Makerere University |
2007-01 | PHASE4 |
| NCT00098293 | COMPLETED | HIV-1 |
ViiV Healthcare |
2004-11 | PHASE3 |
| NCT00318123 | COMPLETED | HIV Infections |
Germans Trias i Pujol Hospital |
2004-04 | PHASE3 |
| NCT00344760 | COMPLETED | HIV Infections |
University of Maryland, Baltimore |
2005-01 | PHASE4 |
| NCT00314626 | COMPLETED | HIV Infections |
Germans Trias i Pujol Hospital |
2004-11 | PHASE3 |
| NCT00234923 | COMPLETED | HIV Infection |
Abbott |
2003-08 | PHASE3 |
| NCT00354653 | COMPLETED | CHRONIC HEPATITIS B |
ViiV Healthcare |
2002-02-09 | PHASE4 |
| NCT00131742 | COMPLETED | Chronic Hepatitis B |
Novartis |
2004-07 | PHASE3 |
| NCT00132652 | COMPLETED | Chronic Hepatitis B |
Novartis |
2005-02 | PHASE3 |
| NCT00192621 | COMPLETED | HIV Infections; Dyslipidemias; Glucose Metabolism Disorders; Metabolic Diseases; Lipodystrophy; Cardiovascular Disease |
Kirby Institute |
2004-11 | PHASE4 |
| NCT00041327 | COMPLETED | Lymphoma |
AIDS Malignancy Consortium |
2002-10 | PHASE2 |
| NCT00618176 | COMPLETED | HIV Infections |
Peking Union Medical College |
2005-01 | PHASE4 |
| NCT00084253 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2004-06 | PHASE4 |
| NCT00895596 | COMPLETED | Chronic Hepatitis B |
LG Life Sciences |
2004-03 | PHASE1; PHASE2 |
| NCT00226447 | COMPLETED | Chronic Hepatitis B |
Chinese University of Hong Kong |
2002-12 | PHASE2 |
| NCT01025830 | COMPLETED | HIV/AIDS |
Makerere University |
2006-02 | PHASE4 |
| NCT00057265 | COMPLETED | Chronic Hepatitis B |
Novartis |
2003-02 | PHASE3 |
| NCT00082394 | COMPLETED | Infection, Human Immunodeficiency Virus I; HIV Infection |
GlaxoSmithKline |
2004-04-26 | PHASE4 |
| NCT00094367 | COMPLETED | HIV Infection |
GlaxoSmithKline |
2004-07 | PHASE3 |
| NCT00335192 | COMPLETED | HIV |
Germans Trias i Pujol Hospital |
2005-01 | PHASE4 |
| NCT00116116 | COMPLETED | HIV Infections; AIDS |
Bristol-Myers Squibb |
2002-03 | PHASE4 |
| NCT00035789 | COMPLETED | Chronic Hepatitis B |
Bristol-Myers Squibb |
2001-11 | PHASE3 |
| NCT00004578 | COMPLETED | HIV Infections |
Abbott |
1997-11 | PHASE1; PHASE2 |
| NCT01022801 | COMPLETED | Chronic Hepatitis B |
Bristol-Myers Squibb |
2003-08 | PHASE2 |
| NCT00112047 | COMPLETED | HIV Infections |
Gilead Sciences |
2003-07 | PHASE3 |
| NCT00036608 | COMPLETED | Chronic Hepatitis B |
Bristol-Myers Squibb |
2002-01 | PHASE3 |
| NCT01037166 | COMPLETED | Chronic Hepatitis B |
Bristol-Myers Squibb |
2002-12 | PHASE2 |
| NCT00116298 | COMPLETED | HIV Infections; AIDS |
Bristol-Myers Squibb |
2001-01 | PHASE3 |
| NCT00014937 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00273975 | COMPLETED | HIV Infections |
Boehringer Ingelheim |
2002-01 | PHASE2 |
| NCT00116415 | COMPLETED | HIV Infections; AIDS |
Bristol-Myers Squibb |
2002-03 | |
| NCT00053638 | COMPLETED | HIV Infection |
GlaxoSmithKline |
2003-02 | PHASE3 |
| NCT00038506 | COMPLETED | HIV Infection |
ViiV Healthcare |
2002-03 | PHASE4 |
| NCT00028327 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00044577 | COMPLETED | Infection, Human Immunodeficiency Virus I; HIV Infection |
ViiV Healthcare |
2002-07-16 | PHASE3 |
| NCT00046176 | COMPLETED | Infection, Human Immunodeficiency Virus I; HIV Infection |
ViiV Healthcare |
2002-08-26 | PHASE3 |
| NCT01982396 | COMPLETED | HIV Infection |
PENTA Foundation |
2003-01 | PHASE1 |
| NCT00006443 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00650637 | TERMINATED | Diarrhea |
Pfizer |
2003-01 | PHASE3 |
| NCT00013897 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2001-02 | PHASE3 |
| NCT00000875 | TERMINATED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00124241 | COMPLETED | Hepatitis B |
Novartis |
PHASE2 | |
| NCT00000922 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00034359 | COMPLETED | Hepatitis B, Chronic |
Alexion Pharmaceuticals, Inc. |
2002-02 | PHASE2 |
| NCT00272480 | COMPLETED | HTLV-I-associated Myelopathy |
Imperial College London |
1999-11-08 | PHASE2; PHASE3 |
| NCT00005918 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
2000-06 | PHASE3 |
| NCT01421212 | COMPLETED | Hepatitis B Virus Associated Liver Disease |
Biotest Pharmaceuticals Corporation |
1999-11 | PHASE1; PHASE2 |
| NCT00021463 | COMPLETED | HIV Infections; Lipodystrophy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00158821 | COMPLETED | HIV Infections |
Gilead Sciences |
2000-03 | PHASE3 |
| NCT00002429 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
1999-07 | PHASE3 |
| NCT02249130 | COMPLETED | HIV Infections |
Boehringer Ingelheim |
1999-03 | PHASE2 |
| NCT00002411 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
1998-03 | |
| NCT00000882 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002371 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
1996-06 | PHASE3 |
| NCT00004583 | COMPLETED | HIV Infections |
Abbott |
1999-03 | PHASE3 |
| NCT00031070 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002179 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
PHASE4 | |
| NCT00000901 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00023153 | COMPLETED | HIV Infections; Chronic Hepatitis B |
National Institute of Allergy and Infectious Diseases (NIAID) |
2001-08 | PHASE3 |
| NCT00002386 | COMPLETED | HIV Infections; Hemophilia A |
Merck Sharp & Dohme LLC |
PHASE4 | |
| NCT00000841 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00002401 | COMPLETED | HIV Infections |
Pharmacia and Upjohn |
||
| NCT00000944 | COMPLETED | HIV Infections; Pregnancy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00710216 | WITHDRAWN | Hepatitis B, Chronic |
University of Ulm |
PHASE4 | |
| NCT00080522 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2005-02 | |
| NCT00034086 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00005000 | UNKNOWN | HIV Infections |
Agouron Pharmaceuticals |
1999-12 | PHASE4 |
| NCT00002190 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
PHASE2 | |
| NCT00460850 | TERMINATED | Hepatitis B, Chronic |
Hoffmann-La Roche |
2007-09 | PHASE4 |
| NCT00100581 | COMPLETED | HIV Infections; Hepatitis C |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00043953 | COMPLETED | HIV Infections |
Abbott |
2002-08 | PHASE2 |
| NCT00002369 | COMPLETED | HIV Infections |
Bristol-Myers Squibb |
||
| NCT00002423 | COMPLETED | HIV Infections |
Glaxo Wellcome |
1999-03 | PHASE2 |
| NCT00337922 | COMPLETED | HIV Infection |
GlaxoSmithKline |
2006-07 | PHASE4 |
| NCT00033163 | COMPLETED | HIV Infections; Hepatitis B |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002451 | UNKNOWN | HIV Infections |
Merck Sharp & Dohme LLC |
PHASE2 | |
| NCT00000834 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00001067 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002416 | COMPLETED | HIV Infections |
Triangle Pharmaceuticals |
PHASE3 | |
| NCT00002442 | COMPLETED | HIV Infections |
Glaxo Wellcome |
1999-06 | PHASE2 |
| NCT00338780 | COMPLETED | Chronic Hepatitis B |
Chinese University of Hong Kong |
2000-11 | PHASE4 |
| NCT00051090 | WITHDRAWN | HIV Infections; Hepatitis B |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00000896 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00001080 | WITHDRAWN | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00197613 | COMPLETED | AIDS; HIV Infection |
Harvard School of Public Health (HSPH) |
2002-12 | PHASE3 |
| NCT00004855 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00001095 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000872 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00120354 | COMPLETED | Hepatitis B, Chronic |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2005-07-11 | PHASE4 |
| NCT00120783 | TERMINATED | HIV Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2002-02 | PHASE2 |
| NCT00078247 | COMPLETED | HIV Infections; Tuberculosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2004-10 | PHASE3 |
| NCT00075231 | COMPLETED | HIV Infections |
Abbott |
2003-12 | PHASE2 |
| NCT00013702 | COMPLETED | Hepatitis B; HIV Infection |
National Institute of Allergy and Infectious Diseases (NIAID) |
2001-03 | PHASE2 |
| NCT00004585 | COMPLETED | HIV Infections |
Glaxo Wellcome |
1999-10 | PHASE4 |
| NCT00000878 | COMPLETED | HIV Infections; Pregnancy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00005017 | UNKNOWN | HIV Infections |
Glaxo Wellcome |
PHASE4 | |
| NCT00558493 | COMPLETED | Chronic Hepatitis B |
Bukwang Pharmaceutical |
2007-11 | PHASE4 |
| NCT00000918 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002227 | COMPLETED | HIV Infections |
Dupont Merck |
PHASE2 | |
| NCT00005002 | UNKNOWN | HIV Infections |
Agouron Pharmaceuticals |
PHASE3 | |
| NCT00122226 | UNKNOWN | HIV Infections; HIV-Associated Lipodystrophy Syndrome |
Amsterdam UMC, location VUmc |
2003-01 | PHASE4 |
| NCT00004998 | SUSPENDED | HIV Infections |
Agouron Pharmaceuticals |
1999-11 | PHASE2 |
| NCT00009061 | UNKNOWN | HIV Infections |
Glaxo Wellcome |
2000-11 | PHASE3 |
| NCT00002241 | UNKNOWN | HIV Infections |
Merck Sharp & Dohme LLC |
PHASE2 | |
| NCT00230477 | COMPLETED | Hepatitis B |
University of Washington |
2003-04 | PHASE4 |
| NCT00001075 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00300573 | TERMINATED | HIV Infections; Human Immunodeficiency Virus |
Incyte Corporation |
2006-04 | PHASE2 |
| NCT00002217 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00004736 | COMPLETED | HIV Infections; Tuberculosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000916 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002424 | SUSPENDED | HIV Infections |
Merck Sharp & Dohme LLC |
PHASE2 | |
| NCT00002199 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE3 | |
| NCT00389194 | COMPLETED | HIV Infections |
International Antiviral Therapy Evaluation Center |
2006-04 | PHASE4 |
| NCT00000899 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00040144 | TERMINATED | Chronic Hepatitis B |
Alexion Pharmaceuticals, Inc. |
2002-07 | PHASE2 |
| NCT00158405 | COMPLETED | HIV Infections |
French National Agency for Research on AIDS and Viral Hepatitis |
2002-12 | PHASE3 |
| NCT00002400 | COMPLETED | HIV Infections |
Pharmacia and Upjohn |
||
| NCT00380614 | COMPLETED | Hepatitis B |
Maulana Azad Medical College |
2002-01 | PHASE4 |
| NCT00000919 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00091936 | COMPLETED | HIV Infections; Tuberculosis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2009-08 | |
| NCT00121979 | COMPLETED | HIV Infections |
Pharmasset |
2004-09 | PHASE2 |
| NCT00000923 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00086359 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2004-07 | PHASE3 |
| NCT00000888 | COMPLETED | HIV Infections; Pregnancy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002407 | COMPLETED | HIV Infections |
Weill Medical College of Cornell University |
||
| NCT00000838 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002368 | COMPLETED | HIV Infections |
Boehringer Ingelheim |
PHASE3 | |
| NCT00001108 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00004981 | UNKNOWN | HIV Infections |
Glaxo Wellcome |
PHASE3 | |
| NCT00000865 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00001968 | COMPLETED | Acquired Immunodeficiency Syndrome; HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
2000-01 | PHASE1 |
| NCT00001084 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002409 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE3 | |
| NCT00002410 | COMPLETED | HIV Infections |
Dupont Merck |
PHASE3 | |
| NCT00001087 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00004999 | SUSPENDED | HIV Infections |
Agouron Pharmaceuticals |
1999-08 | PHASE2 |
| NCT00256828 | COMPLETED | HIV Infections |
Clinical Trial Agency of HIV Study Group |
2004-06 | PHASE4 |
| NCT00006578 | WITHDRAWN | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
||
| NCT00002233 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE2 | |
| NCT00006190 | COMPLETED | HIV Infections; Lipodystrophy |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2000-11 | PHASE4 |
| NCT00014014 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00000887 | COMPLETED | HIV Infections; Pregnancy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002108 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00127972 | COMPLETED | HIV Infections |
International Antiviral Therapy Evaluation Center |
2004-02 | PHASE4 |
| NCT00001094 | WITHDRAWN | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002155 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
||
| NCT00489151 | UNKNOWN | Hepatitis B |
Hospital Authority, Hong Kong |
2005-06 | |
| NCT00162643 | UNKNOWN | Acquired Immunodeficiency Syndrome |
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
2004-12 | PHASE4 |
| NCT00002183 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE1 | |
| NCT00085943 | COMPLETED | HIV Infection; Infection, Human Immunodeficiency Virus |
GlaxoSmithKline |
2004-05 | PHASE3 |
| NCT00000952 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00011895 | UNKNOWN | HIV Infections |
GlaxoSmithKline |
2001-02 | PHASE4 |
| NCT00000831 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00516945 | COMPLETED | Hepatitis B; Neoplasms |
Hospital Authority, Hong Kong |
2004-09 | |
| NCT00002184 | COMPLETED | HIV Infections |
Gilead Sciences |
PHASE2 | |
| NCT00005764 | COMPLETED | HIV Infections; Lipodystrophy |
Glaxo Wellcome |
2000-05 | PHASE4 |
| NCT00002162 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
PHASE2 | |
| NCT00013520 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00002389 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE3 | |
| NCT00199979 | UNKNOWN | Hiv Infection With Antiretroviral Therapy Indication; CD4 Below 350/µL or Below 15% |
MEDEX |
2005-04 | PHASE3 |
| NCT00002320 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE3 | |
| NCT00002376 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
PHASE4 | |
| NCT00001091 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002367 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
PHASE3 | |
| NCT00002203 | COMPLETED | HIV Infections |
Glaxo Wellcome |
||
| NCT00140725 | COMPLETED | Chronic Hepatitis B |
GlaxoSmithKline |
2000-04 | PHASE3 |
| NCT00001085 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00001068 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002379 | COMPLETED | HIV Infections |
Gilead Sciences |
PHASE2 | |
| NCT00000940 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
1999-05 | PHASE2 |
| NCT00000891 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000920 | COMPLETED | HIV Infections; Pregnancy |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE1 | |
| NCT00002245 | COMPLETED | HIV Infections |
Glaxo Wellcome |
1999-04 | PHASE3 |
| NCT00002378 | COMPLETED | HIV Infections |
Hoffmann-La Roche |
PHASE3 | |
| NCT00000870 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000885 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00201318 | COMPLETED | Non-Hodgkin's Lymphoma |
National Health Research Institutes, Taiwan |
2001-09 | PHASE2 |
| NCT00002208 | COMPLETED | HIV Infections |
Merck Sharp & Dohme LLC |
PHASE3 | |
| NCT00102206 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00002436 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE3 | |
| NCT00001083 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE2 | |
| NCT00000903 | COMPLETED | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID) |
PHASE3 | |
| NCT00040157 | TERMINATED | HIV Infections |
Alexion Pharmaceuticals, Inc. |
PHASE2 | |
| NCT00002195 | COMPLETED | HIV Infections |
Glaxo Wellcome |
PHASE3 | |
| NCT00008554 | UNKNOWN | HIV Infections |
Glaxo Wellcome |
2000-11 | PHASE3 |
(data from https://clinicaltrials.gov, updated on 2026-08-14)
Check the
Lamivudine (3TC, BCH-189)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Lamivudine (3TC, BCH-189) Solubility in DMSO
- Lamivudine (3TC, BCH-189) Stock Solution
- Lamivudine (3TC, BCH-189) Storage
- Lamivudine (3TC, BCH-189) Stability
- Lamivudine (3TC, BCH-189) Molecular Weight
- Lamivudine (3TC, BCH-189) SMILES
- Lamivudine (3TC, BCH-189) CAS Number
- Lamivudine (3TC, BCH-189) Chemical Structure (2D and 3D)
- Lamivudine (3TC, BCH-189) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.